Close Menu

Accelerate Diagnostics

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.

New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.

The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.

The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.

The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.

Despite the array of tests available, some lab directors are still seeking broader functionalities and capabilities from the systems they purchase.  

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.